Juvenile Idiopathic Arthritis
Genentech announced that the FDA has approved ACTPen autoinjector for Actemra as a new formulation for adults with moderate to severe active RA.
Rates of biologic drug survival and suspension by remission were both higher in those who initiated biologic treatment at <16 years.
Rituximab may be an effective treatment option for many patients with juvenile idiopathic arthritis who did not respond to other therapies.
Researchers sought to quantify the annual incidence of new-onset uveitis following JIA diagnosis and identify associated risk factors.
Psychological Flexibility Improves Resilience in Children With Juvenile Idiopathic Arthritis and Their ParentsNovember 08, 2018
Psychological flexibility in children with juvenile idiopathic arthritis and in their parents may represent resilience factors for dealing with pain and disability associated with the condition.
Researchers evaluated the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis.
For a more precise assessment of disease activity and treatment effectiveness in individuals with JIA, inclusion of MCP joints should be considered in the scoring system.
The FDA has approved Actemra SC for the treatment of active systemic JIA alone or in combination with methotrexate in patients ≥2 years old.
There is an unmet need for mental health interventions that address illness-related issues affecting youth with rheumatologic conditions.
Prediction models of outcomes in juvenile idiopathic arthritis have acceptable precision and require only readily available baseline variables.
The investigators sought to evaluate the time patients were in remission after discontinuing biologic therapy for the treatment of JIA.
The FDA has approved the subcutaneous formulation of Actemra for the treatment of active polyarticular juvenile idiopathic arthritis.
Baseline depressive symptoms were associated with pain and disability in adolescents with juvenile idiopathic arthritis.
Researchers evaluated the safety and efficacy of adalimumab and infliximab in the treatment of juvenile idiopathic arthritis-associated uveitis in patients treated for at least 2 years.
Investigators aimed to examine the use of treatment targets in juvenile idiopathic arthritis in terms of joint limitations, functional ability, psychosocial health, and pain levels.
The SHARE initiative has provided recommendations for the diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis.
Clinical Features Identified in Enthesitis-Related Juvenile Idiopathic Arthritis, Juvenile SpondyloarthritisApril 20, 2018
Results confirm that juvenile spondyloarthritis is characterized by its peripheral pattern at disease onset, with peripheral arthritis and enthesitis.
The Epstein-Barr virus EBNA2 protein and many coclustering human transcription factors occupied nearly half of SLE risk loci.
Abnormal ultrasound findings were common in patients with juvenile idiopathic arthritis with clinically inactive disease.
Researchers sought to determine the predictors of disease flare after anti-TNF therapy discontinuation in children with polyarticular forms of juvenile idiopathic arthritis with sustained clinically inactive disease.
High neutrophil counts decreased after initiation of recombinant interleukin-1 receptor agonist therapy in systemic-onset juvenile idiopathic arthritis.
Children with juvenile idiopathic arthritis, pediatric inflammatory bowel disease, and pediatric plaque psoriasis had an increased incidence of childhood malignancies, regardless of TNFi exposure.
Abnormality on an ultrasound examination significantly increased the risk for flare in patients with juvenile idiopathic arthritis.
The goal of consensus treatment plans is to drive a cycle of innovation and replacement that allows the addition of new treatments and the removal of unused or ineffective strategies.
Autoantibodies that recognize cytosolic 5′-nucleotidase 1A were detected in about 25% of patients with juvenile myositis and juvenile idiopathic arthritis.
Treatment response was most significant in patients taking either tocilizumab or an interleukin-1 inhibitor.
Adalimumab was well tolerated and associated with persistent uveitis improvement in most cases.
An increase in disease activity 6 weeks postpartum suggests the need for tight follow-up of women with juvenile idiopathic arthritis.
Chronic inflammatory rheumatologic diseases benefit from early anti-inflammatory treatment; however, interdisciplinary approaches may be necessary for identifying and managing noninflammatory joint pain.
The objective of this study is to determine whether the JADAS or cJADAS would accurately predict patients with JIA in need of treatment escalation to anti-TNF after starting MTX.
Rheumatology Advisor Articles
- One-Session Intervention for Hand OA Improved Grip Strength, Patient Satisfaction
- Exercise, TNFi Provide Differential Benefits for Cardiovascular Health in Rheumatoid Arthritis
- Improving RA Diagnosis With Use of Anti-ACPAs
- Anti-Drug Antibody Incidence Risk in RA Increases Over Time With Adalimumab, Infliximab
- MBDA Scores Reflect Response to Rituximab Treatment in Rheumatoid Arthritis
- Circadian Rhythm in Rheumatoid Arthritis: Using Chronotherapy to Improve Outcomes
- Inflammatory Arthritis and the Gut Microbiome: Do Microbes Hold the Key to New Treatments?
- Examining Insurance Complications in the Shared Decision Making Process for Rheumatoid Arthritis
- Filgotinib Safe, Effective for Treatment of Active Ankylosing Spondylitis
- FDA Fast Track Designation Granted for Investigational Osteoarthritis Treatment
- Ultrasonography in Gout: Potential Applications for Diagnosis and Patient Monitoring
- AMA Code of Medical Ethics Guides Physicians in Fighting Harmful Online Health Information
- Immunogenicity of Golimumab Validated Using Novel Anti-Drug Antibody Detection Assay
- Poor Vitamin K Status Linked to Low BMD, Increased Fracture Risk in ESRD
- Most Insured Patients Not Using Online Portals